Pioneering neuro-metabolic therapies for high-need CNS disorders Two lead programs: an ASO for sporadic and genetic ALS patients targeting lipid biology, and an oral small molecule for schizophrenia targeting glutamate biology Lead programs on track for INDs this year, with clinical data in 2025 Additional pipeline programs in Alzheimer’s disease, epilepsy, and depression Pipeline Program […]
Investors 2
Mentions in press and media 3
| Date | Title | Description |
| 27.08.2025 | Leal Therapeutics Raises $30M in Series A Funding | Leal Therapeutics, a Worcester, MA-based biotechnology company developing novel therapeutics for patients with disorders of the central nervous system (CNS), raised $30M in Series A funding.
The round was led by SV Health Investors’ Dementi... |
| - | Leal Therapeutics | “Pioneering neuro-metabolic therapies for high-need CNS disorders Two lead programs: an ASO for sporadic and genetic ALS patients targeting lipid biology, and an oral small molecule for schizophrenia targeting glutamate biology Lead program... |
| - | Leal Therapeutics | “Pioneering precision medicines for high-need CNS disorders Two lead programs: an ASO for sporadic and genetic ALS patients targeting lipid biology, and an oral small molecule for schizophrenia targeting glutamate biology Lead programs on t... |
Reviews 0
